New China Life Insurance (01336) Report Interpretation

Overview

This post-1H26 earnings update balances better investment performance and higher contractual-service-margin assumptions against weaker new-business expectations in bancassurance. Goldman Sachs keeps a Sell rating on both share classes while lowering its price targets.

Core views

Goldman Sachs raises FY26-28E net-profit estimates by 0-3%, driven by a 3% increase in its CSM balance estimates and better-than-expected investment results in 1H26. The higher CSM balance supports greater expected CSM release, while the investment outcome improves projected earnings. The resulting FY26-28E book-value estimates increase by 1-2%, although unfavorable yield movements and OCI equity losses partly offset the benefit. The report cuts FY26-28E VONB estimates by 5-6%. It attributes the reduction to a larger-than-expected active move away from single-premium products in the bancassurance channel, along with continuing bancassurance sales weakness under enhanced expense guidelines. A 0.3 percentage-point increase in the assumed VONB margin partly offsets these pressures, but not enough to prevent lower VONB and first-year-premium forecasts. The updated estimates show FY26E net profit of Rmb31,592 million, 3% above the prior estimate, followed by Rmb20,469 million in FY27E and Rmb21,054 million in FY28E. FY26E CSM is forecast at Rmb192,075 million, 3% above the earlier forecast. VONB is projected at Rmb10,414 million, Rmb11,020 million and Rmb11,630 million in FY26E-FY28E, respectively, representing cuts of 5%, 6% and 6%; FYP is reduced by 7% in each of those years. The report forecasts VONB margins of 17.6%, 17.4% and 17.2%, each 0.3 percentage points above prior assumptions. Goldman Sachs lowers its 12-month ROA-based target prices to HK$38.0 for 1336.HK and Rmb50.5 for 601336.SS, from HK$39.0 and Rmb52.0. The valuation multiples remain unchanged at 0.8x FY27E P/B for the H share and 1.2x for the A share. Against closing prices of HK$50.60 and Rmb62.25 on 4 September 2026, the targets imply 24.9% and 18.9% downside. The firm therefore maintains Sell on both share classes.

Analysis framework

The report updates forward earnings, book value, CSM, VONB and sales forecasts after 1H26 results, linking changes in product mix, bancassurance sales and investment performance to profitability and value creation. It then applies a 12-month ROA-based target-price framework, presented alongside FY27E P/B multiples.

Methodology notes

• Other

  ROA-based target-price methodology

  Goldman Sachs bases its 12-month price targets on return on assets, using the approach to translate its updated operating and earnings assumptions into target prices.

• Valuation methodsPB valuation

  Price-to-book valuation comparison

  The report presents the revised targets as implying FY27E P/B multiples of 0.8x for H shares and 1.2x for A shares.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• New China Life Insurance (H) (1336.HK)

  Primary covered H-share security; target price is reduced following the post-1H26 estimate update.

  Strengths

  Higher projected CSM release and better-than-expected 1H26 investment results support earnings estimates.

  Weaknesses

  Bancassurance sales weakness and a shift away from single-premium products reduce VONB forecasts.

  Comparison

  Target implies 0.8x FY27E P/B, unchanged.

  Risks

  A-share market rally, improved cost discipline, sustained NBV growth, greater OCI debt allocation, or a more aggressive dividend policy could challenge the Sell view.

• New China Life Insurance (A) (601336.SS)

  Primary covered A-share security; target price is reduced following the post-1H26 estimate update.

  Strengths

  Higher projected CSM release and better-than-expected 1H26 investment results support earnings estimates.

  Weaknesses

  Bancassurance sales weakness and a shift away from single-premium products reduce VONB forecasts.

  Comparison

  Target implies 1.2x FY27E P/B, unchanged.

  Risks

  An A-share market rally, improved cost discipline, sustained NBV growth, greater OCI debt allocation, or a more aggressive dividend policy could challenge the Sell view.

Key data

• FY26E net profitRmb31,592 million3% above the prior estimate; forecast year-on-year change of -13%.
• FY27E net profitRmb20,469 million1% above the prior estimate; forecast year-on-year change of -35%.
• FY26E CSMRmb192,075 million3% above the prior estimate.
• FY26E-FY28E VONB revision-5%, -6%, -6%Reflects weaker bancassurance product mix and sales assumptions.
• FY26E-FY28E VONB margin17.6%, 17.4%, 17.2%Each forecast is 0.3 percentage points above the prior estimate.
• H-share target and priceHK$38.00 target; HK$50.60 price24.9% downside; price as of 4 September 2026 close.
• A-share target and priceRmb50.50 target; Rmb62.25 price18.9% downside; price as of 4 September 2026 close.

Impact & implications

The report sees improved investment results and higher CSM release as insufficient to offset weaker new-business value expectations from bancassurance. The reduced targets and maintained Sell rating reflect the projected downside to both share classes.

Risks

• An A-share market rally could benefit NCI given its greater leverage to investment results.
• Improved cost discipline could lift long-term ROE and shareholder returns.
• Sustained NBV growth from efficiency gains could exceed expectations.
• Greater allocation to OCI debt could mitigate adverse effects from declining bond yields.
• A more aggressive future dividend policy could provide upside.